Stay updated with breaking news from Cinque Terra. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and officials are pushing drugmakers to study lower doses early in the research process.
For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.
Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable. Harsh side effects from powerful cancer drugs have long been accepted as a trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. The U.S. Food and Drug Administration is pushing drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. One group is planning a study to test whether lower doses of two new drugs will work for breast cancer that has spread.
Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable. Harsh side effects from powerful cancer drugs have long been accepted as a trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. The U.S. Food and Drug Administration is pushing drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. One group is planning a study to test whether lower doses of two new drugs will work for breast cancer that has spread.
Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable. Harsh side effects from powerful cancer drugs have long been accepted as a trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. The U.S. Food and Drug Administration is pushing drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. One group is planning a study to test whether lower doses of two new drugs will work for breast cancer that has spread.